ArticleACS chemical neuroscience2013
APP+, a fluorescent analogue of the neurotoxin MPP+, is a marker of catecholamine neurons in brain tissue, but not a fluorescent false neurotransmitter.
Article in ACS chemical neuroscience, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Self-Assembled Vesicles of Emissive Surfactants in Water: Structural Characterization and Photophysical Insights.The journal of physical chemistry. B · 2025Article
- Chronic adulthood exposure to bisphenol A causes behavioral changes via suppressing dopamine transporter trafficking.Scientific reports · 2025Article
- Oxa-Iboga alkaloids lack cardiac risk and disrupt opioid use in animal models.Nature communications · 2024Article
- Molecular Design of SERTlight: A Fluorescent Serotonin Probe for Neuronal Labeling in the Brain.Journal of the American Chemical Society · 2024Article
- 5-HT_FAsTR: a versatile, label-free, high-throughput, fluorescence-based microplate assay to quantify serotonin transport and release.Scientific reports · 2024Article
- Ethanol inhibits dopamine uptake via organic cation transporter 3: Implications for ethanol and cocaine co-abuse.Molecular psychiatry · 2023Article
- Chemical Targeting of Rhodol Voltage-Sensitive Dyes to Dopaminergic Neurons.ACS chemical neuroscience · 2022Article
- The chemical tools for imaging dopamine release.Cell chemical biology · 2021Review
- Handling of intracellular KeLife · 2021Article
- Functional characterization of N-octyl 4-methylamphetamine variants and related bivalent compounds at the dopamine and serotonin transporters using CaToxicology and applied pharmacology · 2021Article
- Chemical Targeting of Voltage Sensitive Dyes to Specific Cells and Molecules in the Brain.Journal of the American Chemical Society · 2020Article
- Heterogeneity of dopamine release sites in health and degeneration.Neurobiology of disease · 2020Review
- Clustered Kv2.1 decreases dopamine transporter activity and internalization.The Journal of biological chemistry · 2019Article
- Toward Serotonin Fluorescent False Neurotransmitters: Development of Fluorescent Dual Serotonin and Vesicular Monoamine Transporter Substrates for Visualizing Serotonin Neurons.ACS chemical neuroscience · 2018Article
- Identification of Fluorescent Small Molecule Compounds for Synaptic Labeling by Image-Based, High-Content Screening.ACS chemical neuroscience · 2018Article
- Characteristics of the mitochondrial and cellular uptake of MPP+, as probed by the fluorescent mimic, 4'I-MPP.PloS one · 2018Article
- Elevated mitochondria-coupled NAD(P)H in endoplasmic reticulum of dopamine neurons.Molecular biology of the cell · 2016Article
- Synaptic optical imaging platforms: Examining pharmacological modulation of neurotransmitter release at discrete synapses.Neuropharmacology · 2015Review
- Successful Treatment of Intracranial Glioblastoma Xenografts With a Monoamine Oxidase B-Activated Pro-Drug.EBioMedicine · 2015Article
- Action potentials and amphetamine release antipsychotic drug from dopamine neuron synaptic VMAT vesicles.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
We have previously introduced fluorescent false neurotransmitters (FFNs) as optical reporters that enable visualization of individual dopaminergic presynaptic terminals and their activity in the brain. In this context, we examined the fluorescent pyridinium dye 4-(4-dimethylamino)phenyl-1-methylpyridinium (APP+), a fluorescent analogue of the dopaminergic neurotoxin MPP+, in acute mouse brain tissue. APP+ is a substrate for the dopamine transporter (DAT), norepinephrine transporter (NET), and serotonin transporter (SERT), and as such represented a candidate for the development of new FFN probes. Here we report that APP+ labels cell bodies of catecholaminergic neurons in the midbrain in a DAT- and NET-dependent manner, as well as fine dopaminergic axonal processes in the dorsal striatum. APP+ destaining from presynaptic terminals in the dorsal striatum was also examined under the conditions inducing depolarization and exocytotic neurotransmitter release. Application of KCl led to a small but significant degree of destaining (approximately 15% compared to control), which stands in contrast to a nearly complete destaining of the new generation FFN agent, FFN102. Electrical stimulation of brain slices at 10 Hz afforded no significant change in the APP+ signal. These results indicate that the majority of the APP+ signal in axonal processes originates from labeled organelles including mitochondria, whereas only a minor component of the APP+ signal represents the releasable synaptic vesicular pool. These results also show that APP+ may serve as a useful probe for identifying catecholaminergic innervations in the brain, although it is a poor candidate for the development of FFNs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.